| Product NDC: | 64764-175 |
| Proprietary Name: | Dexilant |
| Non Proprietary Name: | dexlansoprazole |
| Active Ingredient(s): | 60 mg/1 & nbsp; dexlansoprazole |
| Administration Route(s): | ORAL |
| Dosage Form(s): | CAPSULE, DELAYED RELEASE |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 64764-175 |
| Labeler Name: | Takeda Pharmaceuticals America, Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA022287 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20100412 |
| Package NDC: | 64764-175-19 |
| Package Description: | 1000 CAPSULE, DELAYED RELEASE in 1 BOTTLE (64764-175-19) |
| NDC Code | 64764-175-19 |
| Proprietary Name | Dexilant |
| Package Description | 1000 CAPSULE, DELAYED RELEASE in 1 BOTTLE (64764-175-19) |
| Product NDC | 64764-175 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | dexlansoprazole |
| Dosage Form Name | CAPSULE, DELAYED RELEASE |
| Route Name | ORAL |
| Start Marketing Date | 20100412 |
| Marketing Category Name | NDA |
| Labeler Name | Takeda Pharmaceuticals America, Inc. |
| Substance Name | DEXLANSOPRAZOLE |
| Strength Number | 60 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Proton Pump Inhibitor [EPC],Proton Pump Inhibitors [MoA] |